Article Text

Download PDFPDF
Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • Contributors LDS and SB conceived the work, contributed to the analysis and interpretation of data, and drafted the manuscript. BD'O and GS contributed to the acquisition of data and revised the manuscript critically. AM contributed to the interpretation of data and revised the manuscript critically for important intellectual content. CM conceived the work and revised the manuscript critically for important intellectual content. All the authors provided final approval of the version to be published.

  • Funding This study was supported in part by funding from the IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

  • Competing interests SB reports grant/research support from Pfizer and personal fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Pfizer and Sanofi. CM reports personal fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Pfizer, Roche and Sanofi.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.